Adipogenic/lipid, inflammatory, and mitochondrial parameters in subcutaneous adipose tissue of untreated HIV-1-infected long-term nonprogressors: Significant alterations despite low viral burden

Journal of Acquired Immune Deficiency Syndromes

Volumn 61, Issue 2, 2012, Pages 131-137

  Vidal, Francesc ^a   Domingo, Pere ^b   Villarroya, Francesc ^c   Giralt, Marta ^c   López Dupla, Miguel ^a   Gutiérrez, Mar ^b   Gallego Escuredo, Jose M ^c   Peraire, Joaquim ^a   Viladés, Consuelo ^a   Veloso, Sergi ^a   Mateo, Gracia ^b   Guallar, Jordi P ^c   Richart, Cristóbal ^a  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

adipose tissue; HIV; inflammation; long term nonprogressors; mitochondria

Indexed keywords

CYTOCHROME C OXIDASE; CYTOCHROME C OXIDASE SUBUNIT II; FATTY ACID BINDING PROTEIN 4; INTERLEUKIN 18; LIPOPROTEIN LIPASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NUCLEAR RESPIRATORY FACTOR 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; T6 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABDOMINAL SUBCUTANEOUS FAT; ADIPOCYTE; ADULT; ARTICLE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LONG TERM NONPROGRESSOR; MALE; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; CYTOKINES; FEMALE; GENE EXPRESSION PROFILING; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HUMANS; LIPID METABOLISM; MALE; MITOCHONDRIA; SUBCUTANEOUS FAT; VIRAL LOAD;

EID: 84867007875     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31825c3a68     Document Type: Article

References (38)

1. Villarroya F, Domingo P, Giralt M. Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity. Trends Pharmacol Sci. 2005;26:88-93.
2. Miller J, Carr A, Emery S, et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med. 2003;4:293-301.
3. Palella FJ Jr, Cole SR, Chmiel JS, et al. Anthropometrics and examiner-reported body habitus abnormalities in the multicenter AIDS cohort study. Clin Infect Dis. 2004;38:903-907.
4. Lopez S, Garrabou G, Martinez E, et al. Mitochondrial studies in adipose tissue of HIV-infected patients without fat redistribution. Antivir Ther. 2004;9:L20.
5. Giralt M, Domingo P, Guallar JP, et al. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV-1/HAART-asso-ciated lipodystrophy. Antivir Ther. 2006;11:729-740.
6. Boothby M, McGee KC, Tomlinson JW, et al. Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months. Antivir Ther. 2009;14:1089-1100.
7. Kino T, Chrousos GP. Human immunodeficiency virus type-1 accessory protein Vpr: a causative agent of the AIDS-related insulin resistance/ lipodystrophy syndrome? Ann N Y Acad Sci. 2004;1024:153-167.
8. Kino T, De Martino MU, Charmandari E. HIV-1 accessory protein Vpr inhibits the effect of insulin on the Foxo subfamily of forkhead transcription factors by interfering with their binding to 14-3-3 proteins: potential clinical implications regarding the insulin resistance of HIV-1-infected patients. Diabetes. 2005;54:23-31.
9. Muthumani K, Choo AY, Premkumar A, et al. Human immunodeficiency virus type 1 (HIV-1) Vpr-regulated cell death: insights into mechanism. Cell Death Differ. 2005;12(suppl 1):962-970.
10. Shrivastav S, Kino T, Cunningham T, et al. Human immunodeficiency virus (HIV)-1 viral protein R suppresses transcriptional activity of per-oxisome proliferator-activated receptor g and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy. Mol Endocrinol. 2008;22:234-247.
11. Kamiska M, Francin M, Shalak V, et al. Role of HIV-1 Vpr-induced apoptosis on the release of mitochondrial lysyl-tRNA synthetase. FEBS Lett. 2007;581:3105-3110.
12. Van Beekum O, Brenkman AB, Grøntved L, et al. The adipocyte acetyl-transferase Tip60 targets activation function 1 of peroxisome proliferator-activated receptor g. Endocrinology. 2008;149:1840-1849.
13. Veloso S, Olona M, García F, et al. Effect of TNF-alpha genetic variants and CCR5 Delta 32 on the vulnerability to HIV-1 infection and disease progression in Caucasian Spaniards. BMC Med Genet. 2010;11:63.
14. Casado C, Colombo S, Rauch A, et al. Host and viral genetic correlates of clinical definitions of HIV-1 disease progression. PLoS One. 2010;5: e11079.
15. Chang K, Truong D, Shangari N, et al. Drug-induced mitochondrial toxicity. Expert Opin Drug Metab Toxicol. 2005;1:655-669.
16. Côté HC, Gerschenson M, Walker UA, et al. Quality assessment of human mitochondrial DNA quantification: MITONAUTS, an international multicentre survey. Mitochondrion. 2011;11:520-527.
17. Miró O, López S, Martínez E, et al. Mitochondrial effects of HIV infection on the peripheral blood mononuclear cells of HIV-infected patients who were never treated with antiretroviral drugs. Clin Infect Dis. 2004;39:710-716.
18. Peraire J, Miró O, Saumoy M, et al. HIV-1-infected long-term non-pro-gressors have milder mitochondrial impairment and lower mitochondri-ally-driven apoptosis in peripheral blood mononuclear cells than typical progressors. Curr HIV Res. 2007;5:467-473.
19. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodys-trophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
20. Kannisto K, Sutinen J, Korsheninnikova E, et al. Expression of adipo-genic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy. AIDS. 2003;17:1753-1762.
21. Gougeon ML, Pénicaud L, Fromenty B, et al. Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations. Antivir Ther. 2004;9:161-177.
22. Escoté X, Miranda M, Veloso S, et al. Lipodystrophy and insulin resistance in combination antiretroviral treated HIV-1-infected patients: implication of resistin. J Acquir Immune Defic Syndr. 2011;57:16-23.
23. Vilarroya F, Domingo P, Giralt M. Mechanisms of antiretroviral-induced mitochondrial dysfunction in adipocytes and adipose tissue: in-vitro, animal and human adipose tissue studies. Curr Opin HIV AIDS. 2007; 2:261-267.
24. Otake K, Omoto S, Yamamoto T, et al. HIV-1 Nef protein in the nucleus influences adipogenesis as well as viral transcription through the perox-isome proliferator-activated receptors. AIDS. 2004;18:189-198.
25. Romani B, Engelbrecht S. Human immunodeficiency virus type 1 Vpr: functions and molecular interactions. J Gen Virol. 2009;90:1795-1805.
26. Romani B, Engelbrecht S, Glashoff RH. Functions of Tat: the versatile protein of human immunodeficiency virus type 1. J Gen Virol. 2010;91: 1-12.
27. Villarroya J, Díaz-Delfin J, Hyink D, et al. HIV type-1 transgene expression in mice alters adipose tissue and adipokine levels: towards a rodent model of HIV type-1 lipodystrophy. Antivir Ther. 2010;15: 1021-1028.
28. Domingo P, Vidal F, Domingo JC, et al. Tumour necrosis factor alpha in fat redistribution syndromes associated with combination antiretroviral therapy in HIV-1-infected patients: potential role in subcutaneous adipo-cyte apoptosis. Eur J Clin Invest. 2005;35:771-780.
29. Miranda M, Chacón MR, Vidal F, et al. LMNA messenger RNA expression in highly active antiretroviral therapy-treated HIV-positive patients. J Acquir Immune Defic Syndr. 2007;46:384-389.
30. Bastard JP, Caron M, Vidal H, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet. 2002;359:1026-1031.
31. Kotler DP, Ionescu G, Johnson JA, et al. Studies in adipose tissue metabolism in human immunodeficiency virus-associated lipodystrophy. Clin Infect Dis. 2003;37(suppl 2):S47-S51.
32. Stankov MV, Behrens GM. Contribution of inflammation to fat redistribution and metabolic disturbances in HIV-1 infected patients. Curr Pharm Des. 2010;16:3361-3371.
33. Grunfeld C, Delaney JA, Wanke C, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS. 2009;23:1841-1849.
34. Caron-Debarle M, Lagathu C, Boccara F, et al. HIV-associated lipodys-trophy: from fat injury to premature aging. Trends Mol Med. 2010;16: 218-229.
35. Garrabou G, López S, Morén C, et al. Mitochondrial damage in adipose tissue of untreated HIV-infected patients. AIDS. 2011;25:165-170.
36. Dimauro S, Hirano M. Pathogenesis and treatment of mitochondrial disorders. Adv Exp Med Biol. 2009;652:139-170.
37. Nolan D, Hammond E, Martin A, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS. 2003;17: 1329-1338.
38. McComsey GA, Libutti DE, O'Riordan M, et al. Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy and not to HIV infection. Antivir Ther. 2008;13:715-722.